Pharosyn Raises $3 Mn to Expand AI Platform for Biopharma Decision-Making

Other investors in the round include Entrepreneurs First, Transpose Platform, and General Advance.

Pharosyn has spent the past few months using its AI technology in pharmaceutical business and strategy teams. Senior directors at leading pharmaceutical companies now use the platform every day to support important decisions.

The company says its technology helps teams find important insights, answer questions in minutes instead of hours, and work faster. It also allows teams to do deeper analysis and improve their results over time.

“Today, I am pretty proud of our product but the scope for improvement is huge. I know I will look back on it in 6 months and be almost embarrassed – the same way that I look back on earlier in the year – that’s the joy of building super quickly as the tech changes constantly all around us,” said co-founder Joshua Hampson

Mattias Ljungman, founder of Moonfire, says: “Pharosyn’s founders are deeply technical, exceptionally tenacious and ambitious, and determined to be best-in-class globally. They are rare founders who clearly stand out. We could not be more excited to lead this round.”

Founded in 2025, Pharosyn is an AI-powered platform for biopharma companies. It helps companies understand their competitors and make better business decisions.

The platform tracks clinical, regulatory, and commercial data from different sources. It then uses this information to create strategic reports based on each company’s drug pipeline.

Pharosyn was founded by Stephen Cowley and Joshua Hampson, who have backgrounds in AI research and biochemistry from Cambridge University.

The team also has experience using AI for financial forecasting and workplace productivity. Its members also bring years of experience in pharmaceutical strategy, including work at Citeline and leading consulting firms.

Read Also- iPremom Raises €15 Mn to Develop Early Pregnancy Complication Detection Platform